<DOC>
	<DOCNO>NCT01840488</DOCNO>
	<brief_summary>The purpose study determine optimal biological dose ( OBD ) Irosustat ( BN83495 ) postmenopausal woman oestrogen receptor ( ER ) positive locally advanced metastatic breast cancer disease progression prior hormonal therapy . This study design provide necessary information safety dose response BN83495 , give repeat daily oral administration , achieve maximal STS inhibition maximal reduction plasma oestradiol ( E2 ) adiol level . The data obtain used plan clinical study .</brief_summary>
	<brief_title>BN83495 Phase I Post-menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women age 18 whose disease progress first line hormonal therapy advance metastatic breast cancer . Patients two prior hormonotherapy setting define adjuvant first line hormonotherapy Or two line hormonotherapy give advanced metastatic disease Patients prior adjuvant hormonal therapy relapse 12 month adjuvant treatment . Patients two prior chemotherapy treatment define adjuvant first line chemotherapy Or two line chemotherapy give advanced metastatic disease Patients one prior therapy Her2 positive breast cancer Postmenopausal woman , define : ) spontaneous menses total 2 year , ii ) amenorrheic least 12 month serum oestrogen level &lt; 30 pg/mL , LH/FSH &gt; 20 IU/L , chemotherapyinduced amenorrhea least 12 month , iii ) bilateral oophorectomy , radiation castration amenorrheic least 3 month . Histologically cytologically confirm breast cancer . Laboratory documentation ERpositive and/or progesterone receptor ( PR ) positive status . ECOG performance status ≤2 . Adequate bone marrow function determine : Haemoglobin &gt; 10 g/dL , Neutrophil count &gt; 1.5 x 109 per litre , Platelet count &gt; 75 x 109 per litre Satisfactory hepatic function measure : serum bilirubin &lt; 1.5 ULN either ALT AST &lt; 2.5 x ULN ( &lt; 5 x ULN presence liver metastasis ) . Alkaline phosphatase &lt; 2.5 ULN absence liver metastases &lt; 5 x ULN presence liver bone metastasis . Satisfactory renal function measure either serum creatinine value &lt; 1.5 x ULN creatinine clearance ≥60 mL/min . Life expectancy least 12 week . Patients measurable nonmeasurable lesion ( RECIST criterion ) Patients include Optimal Biological Dose ( OBD ) define must measurable lesion ( RECIST criterion ) . Patients progressive central nervous system metastasis . Patients inflammatory breast cancer . Patients mark baseline prolongation QTc interval ( e.g. , repeated demonstration QTcf interval &gt; 450 m ) . Patients history additional risk factor TdP ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) . Patients take concomitant medication know prolong QTc interval ( e.g. , antihistamine , quinolones , antipsychotic etc ) . Patients preexist cardiac failure ( American Heart Association Grade 3 4 ) myocardial infarction within six month prior start study . Patients systolic diastolic blood pressure 100 60 mmHg respectively . Patients uncontrolled abnormality serum potassium , sodium , calcium magnesium level . Patients coexist significant disease systemic infection . Patients uncontrolled diabetes ( applicable additional six patient include OBD define ) . Patients malabsorption . Patients start biphosphonates therapy within 4 week prior start study Patients take drug inhibit carbonic anhydrase II ( CAII ) ( e.g . acetazolamide , brinzolamide , dichlorphenamide , dorzolamide , methazolamide ) . Patients take coumarin like drug ( vitamin K antagonists ) . Patients incapable give informed consent comply protocol . Patients receive previous investigational therapy must stop therapy least 4 week treatment BN83495 . Patients receive previous therapy cancer within less 1 month entry study and/or receive trastuzumab within less 4 month entry study , and/or fulvestrant within less 2 month entry . Patients history hypersensitivity IMP drug similar chemical structure . Patients history , know current , problem alcohol abuse . Patients mental condition render patient unable understand nature , scope possible consequence study , and/or evidence uncooperative attitude . Patients abnormal baseline finding , medical condition laboratory finding , opinion Investigator , might jeopardise patient ' safety decrease chance obtain satisfactory data need achieve objective study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>